What question did this study set out to answer?

To evaluate peri-infusion gut microbiome remodeling and determine its association with clinical response and immune-related toxicities in B-cell lymphoma patients receiving CAR-T cell therapy.

August 16, 2026Journal of Translational MedicineOpen Access

Longitudinal metagenomic profiling of gut microbiome dynamics in B-cell lymphoma patients receiving CAR-T cell therapy

View Full Paper

Ask AI

Bookmark

Authors

ZJZimo JiaMinistry of Education PZPeixian ZhengPeking University HZHaoxuan ZhangPeking University

Discussion

Member takes

Implication

Longitudinal study reveals gut microbiome remodeling linked to treatment response and cytokine release syndrome in B-cell lymphoma, highlighting pre-infusion microbial markers of CAR-T outcomes.

Key Points

To evaluate peri-infusion gut microbiome remodeling and determine its association with clinical response and immune-related toxicities in B-cell lymphoma patients receiving CAR-T cell therapy.
Conducted shotgun metagenomic sequencing on 103 fecal samples from 21 patients with B-cell lymphoma at five timepoints (days −7, 0, 7, 14, and 28 relative to CAR-T infusion).
Analyzed longitudinal taxonomic dynamics and baseline stability using mixed-effects models and centered log-ratio transformations with false discovery rate correction.
Evaluated day −7 clinical and microbial features using exploratory nested cross-validation to predict therapeutic response and cytokine release syndrome.
CAR-T infusion induced early, patient-specific gut microbiome remodeling marked by a transient reduction in alpha diversity and compositional divergence from baseline.
Baseline microbial diversity, overall community structure, and Sutterella and Segatella abundance differed between responders and non-responders, while lower baseline diversity associated with cytokine release syndrome but not neurotoxicity.
Nested cross-validation models achieved AUCs of 0.51 (clinical), 0.55 (microbiome), and 0.72 (combined) for response prediction, and 0.44 (clinical), 0.85 (microbiome), and 0.83 (combined) for cytokine release syndrome prediction.

Cite This Study

Jia et al. (2026) studied this question.

synapsesocial.com/papers/6a81794cf2fb91fc834ac7b4 https://doi.org/10.1186/s12967-026-08814-7

View Full Paper

Ask AI

Bookmark

August 16, 2026Journal of Translational MedicineOpen Access

Longitudinal metagenomic profiling of gut microbiome dynamics in B-cell lymphoma patients receiving CAR-T cell therapy

View Full Paper

Ask AI

Bookmark

Authors

ZJZimo JiaMinistry of Education PZPeixian ZhengPeking University HZHaoxuan ZhangPeking University

Discussion

Member takes

Implication

Longitudinal study reveals gut microbiome remodeling linked to treatment response and cytokine release syndrome in B-cell lymphoma, highlighting pre-infusion microbial markers of CAR-T outcomes.

Key Points

To evaluate peri-infusion gut microbiome remodeling and determine its association with clinical response and immune-related toxicities in B-cell lymphoma patients receiving CAR-T cell therapy.
Conducted shotgun metagenomic sequencing on 103 fecal samples from 21 patients with B-cell lymphoma at five timepoints (days −7, 0, 7, 14, and 28 relative to CAR-T infusion).
Analyzed longitudinal taxonomic dynamics and baseline stability using mixed-effects models and centered log-ratio transformations with false discovery rate correction.
Evaluated day −7 clinical and microbial features using exploratory nested cross-validation to predict therapeutic response and cytokine release syndrome.
CAR-T infusion induced early, patient-specific gut microbiome remodeling marked by a transient reduction in alpha diversity and compositional divergence from baseline.
Baseline microbial diversity, overall community structure, and Sutterella and Segatella abundance differed between responders and non-responders, while lower baseline diversity associated with cytokine release syndrome but not neurotoxicity.
Nested cross-validation models achieved AUCs of 0.51 (clinical), 0.55 (microbiome), and 0.72 (combined) for response prediction, and 0.44 (clinical), 0.85 (microbiome), and 0.83 (combined) for cytokine release syndrome prediction.

Cite This Study

Jia et al. (2026) studied this question.

synapsesocial.com/papers/6a81794cf2fb91fc834ac7b4 https://doi.org/10.1186/s12967-026-08814-7

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark